| 4q12 for PDGFRalpha rearrangement | 5182-1 |
| ABL Kinase Mutation Analysis for Gleevec Resistance | 6290-1 |
| Abnormal aPTT Assessment | 5851-1 |
| Abnormal PT & aPTT Assessment | 5853-7 |
| Abnormal PT Solely | 5852-9 |
| Activated Protein C Resistance (APCR, M) | 5705-9 |
| Activated Protein C Resistance (APCR, S) | 5704-2 |
| Acute Leukemia (Myeloid//Lymphoid) Panel- Technical Component Only | 5516-0 |
| Acute Leukemia (Myeloid/Lymphoid) Panel | 5515-2 |
| Acute Leukemia/MDS | 5116-9 |
| Acute Myelogenous Leukemia (AML-M2) FISH | 5024-5 |
| Acute Myelogenous Leukemia (AML-M2) PCR | 5034-4 |
| Acute Myelogenous Leukemia Prognosis using NPM1 FLT3 and Mutation Analysis | 5988-1 |
| Adenocarcinoma vs. Mesothelioma Profile | 5181-3 |
| AE1/AE3 (Technical Only) | 5108-6 |
| Alpha2 Antiplasmin | 5709-1 |
| AML, ALL by FISH | 5427-0 |
| AML, ALL- PCR | 5037-7 |
| AML-M3 (APL) FISH | 5260-5 |
| AML-M3 (APL) PCR | 5261-3 |
| AML-M4Eo FISH | 5025-2 |
| AML-M4Eo PCR | 5035-1 |
| Anti-Annexin V (5) Antibodies (IgG, IgM) | 5706-7 |
| Anti-Beta2 Glycoprotein 1 (lgG, IgM, IgA) | 5710-9 |
| Anti-Cardiolipin Abs (IgG, IgM, IgA) (Antiphospholipid Ab) | 5720-8 |
| Anti-Phosphatidyl Ethanolamine Antibodies (IgG, IgM) | 5722-4 |
| Anti-Phosphatidylserine Antibodies (IgG, IgM) | 5790-1 |
| Anti-Prothrombin Antibodies (IgG, IgM) | 5820-6 |
| Antiphospholipid Antibody and Lupus Inhibitor Assessment- Basic | 5994-9 |
| Antiphospholipid Antibody and Lupus Inhibitor Assessment- Expanded | 5990-7 |
| Antiplatelet Antibody - Direct | 5702-6 |
| Antiplatelet Antibody - Indirect | 5703-4 |
| Antithrombin Activity (ATIII Activity) - Anti-Xa Based | 5723-2 |
| Antithrombin Activity (ATIIIActivity) - Thrombin Based | 5714-1 |
| Antithrombin Antigen | 5715-8 |
| Arterial and Atherothrombotic Risk- Basic | 5874-3 |
| Arterial and Atherothrombotic Risk- Expanded | 6802-3 |
| B-Cell Lymphoma | 5032-8 |
| Bleeding Diathesis Evaluation | 5997-2 |
| Bleeding Time | 5716-6 |
| Bone Marrow Slide Consultation with Hematopathologist | 5207-6 |
| Bone Marrow Transplant Monitoring | 5066-6 |
| BRAF Mutational Analysis | 5893-3 |
| Burkitt Lymphoma | 5027-8 |
| C-KIT Mutation Analysis, Cell- based | 5179-7 |
| C-Reactive Protein-hs | 5719-0 |
| C4b Binding Protein (C4b-BP) | 5717-4 |
| Carcinoma vs. Lymphoma Profile | 5400-7 |
| CBC, w/Diff & Platelets | 5780-2 |
| Cell Search Circulating Tumor | 6237-2 |
| Chromosomal Analysis | 5250-6 |
| Chronic Lymphocytic Leukemia (CLL) Panel | 5280-3 |
| Chronic Myelogenous Leukemia (CML) FISH | 5265-4 |
| Chronic Myelogenous Leukemia (CML) PCR | 5268-8 |
| CK-903 for Prostate Cancer | 5434-6 |
| CK-903 for Prostate Cancer (Technical Only) | 5404-9 |
| Clot Only (1) | 5202-7 |
| Collagen Binding Assay | 5744-8 |
| Comp. Analysis/Smears For Correlation Only-Smears Returned (1) | 5203-5 |
| Comprehensive Core, Clot and Smears (1) | 5199-5 |
| Core (s) Only (1) | 5200-1 |
| Cytochrome P450 (CYP) 2D6 Pharmacogenomic Analysis | 5287-8 |
| Cytochrome P450 (CYP) 2D6 Pharmacogenomic Analysis (NY Clients) | 5296-9 |
| D-Dimer, Quantitative | 5743-0 |
| DIC Assessment | 5992-3 |
| Dilute Russell Viper Venom Test- Complete | 5730-7 |
| DNA Ploidy for Molar Pregnancy by FLOW Cytometry | 5555-8 |
| DPD-5 FU GENOTYPE | 6285-1 |
| EGFR | 5109-4 |
| EGFR by IHC (Technical Only) | 5403-1 |
| Epidermal Growth Factor Receptor (EGFR) Mutation Analysis | 5295-1 |
| ER/PR (Technical Only) | 5425-4 |
| ER/PR w/ interpretation | 5198-7 |
| ER/PR/DNA/Ki-67 w/ interpretation | 5160-7 |
| ER/PR/DNA/Ki-67/HER2 w/ interpretation | 5162-3 |
| ER/PR/DNA/Ki-67/HER2- Reflex 2+ to HER2 by FISH | 5408-0 |
| ER/PR/HER2 (Technical Only) | 5127-6 |
| ER/PR/HER2 w/ interpretation | 5161-5 |
| ER/PR/HER2-Reflex2+ to Her2 by FISH | 5406-4 |
| ER/PR/Ki-67, Plus DNA (Technical Only) | 5129-2 |
| ER/PR/Ki-67/HER2 (Technical Only) | 5433-8 |
| ER/PR/Ki-67/HER2 w/ interpretation | 5163-1 |
| ER/PR/Ki-67/HER2, Plus DNA | 5131-8 |
| ER/PR/Ki-67/HER2- Reflex 2+ to HER2 by FISH | 5407-2 |
| Euglobulin Clot Lysis | 5770-3 |
| Factor II (2) Clotting Activity (Prothrombin Level) | 5724-0 |
| Factor IX (9) Clotting Activity | 5769-5 |
| Factor V (5) (R2) Polymorphism | 5727-3 |
| Factor V (5) Cambridge | 5763-8 |
| Factor V (5) Clotting Activity | 5725-7 |
| Factor V (5) Leiden Mutation (FVL) | 5726-5 |
| Factor VII (7) Clotting Activity | 5728-1 |
| Factor VIII (8) Clotting Activity | 5729-9 |
| Factor X (10) Antigen | 5736-4 |
| Factor X (10) Chromogenic | 5707-5 |
| Factor X (10) Clotting Activity | 5735-6 |
| Factor XI (11) Clotting Activity | 5737-2 |
| Factor XII (12) Clotting Activity | 5738-0 |
| Factor XIII (13) Activity | 5739-8 |
| Fibrinogen Clottable Activity | 5745-5 |
| Fibrinolytic Evaluation- Standard | 5860-2 |
| Fibrinolytic Evaluation- Standard | 5860-2 |
| FLT3 Mutation Analysis for Acute Myelogenous Leukemia Prognosis | 5178-9 |
| Follicular Lymphoma (FL) | 5270-4 |
| For specific factor inhibitor | 5818-0 |
| GenArray Molecular Karyotyping | 5306-6 |
| General Thrombophilia Assessment for Inherited & Acquired Disorders | 6800-7 |
| Germ cell Tumor Profile | 5194-6 |
| Heparin Cofactor II | 5748-9 |
| Heparin Level (Anti-Xa) | 5761-2 |
| Heparin Platelet Antibody (HIT) | 5746-3 |
| Hepatocellular vs. Cholangiocarcinoma vs. Metastasis Profile | 5193-8 |
| HER2 by FISH | 5262-1 |
| HER2 by IHC | 5171-4 |
| HER2 by IHC (Technical Only) | 5405-6 |
| HER2 BY IHC RFX 2+ TO HER2 by FISH - Technical Only | 5311-6 |
| HER2 by IHC- Reflex 2+ to HER2 by FISH | 5428-8 |
| HER2 FISH -TC Automated | 5259-7 |
| Hereditary Hemochromatosis (HHC) | 3420-7 |
| Hereditary Hemochromatosis (HHC) for NY patients | 2696-3 |
| Hexagonal Phase Assay | 5749-7 |
| HMW Kininogen (Fitzgerald Factor) | 5754-7 |
| Homocysteine | 5755-4 |
| HPV High and Low Risk by ISH | 3412-4 |
| Hyperactive Coagulation Panel | 5993-1 |
| IGH, B-Cell Gene rearrangement, Clonal B cell, B-Cell Receptor, B-Cell Lymphoma | 5278-7 |
| IgVH Mutation Analysis for CLL/SLL | 5223-3 |
| Inhibitor Titer (Quantitative Bethesda Unit) | 5757-0 |
| Irinotecan Toxicity Assessment*- UGT1A1 | 5183-9 |
| JAK-2 EXON 12 in myeloproliferative neoplasms (MPN) | 5307-4 |
| Jak-2 V617F Mutation Analysis in MPNs | 5157-3 |
| K-ras (KRAS) Gene Mutation Detection | 5288-6 |
| Ki-67, IHC with Interpretation | 5152-4 |
| Lipoprotein a, Lp (a) | 5758-8 |
| Lupus Inhibitor Screen | 5817-2 |
| Lymphoma (NHL) vs. Reactive Hyperplasia | 5103-7 |
| Lymphoproliferative Disorders Analysis | 5535-0 |
| Lymphoproliferative Disorders Analysis- Technical Component Only | 5536-8 |
| Mantle cell Lymphoma (MCL) | 5026-0 |
| Micrometastasis Breast Cancer- Lymph Node | 5170-6 |
| Micrometastasis Colon cancer- Lymph Node | 5124-3 |
| Micrometastasis Melanoma- Lymph Node (S100, Melan A, HMB45) | 5126-8 |
| Mixing Study – aPTT | 5830-5 |
| Mixing Study – PT | 5840-4 |
| MPL515 for JAK2 Negative Myeloproliferative Disorder Patients | 5272-0 |
| MTHFR (A1298C) Mutation | 5765-3 |
| MTHFR (C677T) Mutation | 5764-6 |
| Myelodysplastic Syndrome (MDS) Panel | 5281-1 |
| Neuroendocrine Neoplasm Profile | 5195-3 |
| NHL- (Diffuse Large B-Cell Lymphoma, FL) | 5028-6 |
| NPM1 Mutation Analysis for Acute Myelogenous Leukemia | 5269-6 |
| Oncotype DX Breast Cancer Assay | 5864-4 |
| p53 | 5153-2 |
| PAI 4G/5G Polymorphism | 5768-7 |
| Partial Thromboplastin (aPTT) Standard | 5835-4 |
| Partial Thromboplastin Time (aPTT) Lupus Sensitive | 5771-1 |
| Plasma Cell Analysis | 5573-1 |
| Plasma Cell Analysis-Technical Component Only | 5574-9 |
| Plasma Cell Dyscrasia (PCD) Panel | 5282-9 |
| Plasma Cell Dyscrasia/MM | 5579-8 |
| Plasminogen Activator Inhibitor Activity (PAI-1) | 5774-5 |
| Plasminogen Activity | 5775-2 |
| Platelet Aggregation Study | 5876-8 |
| Platelet Antibody Identification | 5776-0 |
| Platelet Count | 5777-8 |
| Platelet Neutralizing Procedure (PNP) | 5784-4 |
| Platelet Size Analysis-Smear review | 5778-6 |
| PNH Panel- Technical Component Only | 5185-4 |
| PNH with FLAER Panel | 5564-0 |
| Pregnancy Thrombophilia Assessment | 6801-5 |
| Prekallikrein (Fletcher Factor) Clotting Activity | 5779-4 |
| Prostate Cancer Profile (CK903, p63, P504S) | 5097-1 |
| Prostate Cancer Profile (CK903, p63, P504S) (technical Only) | 5104-5 |
| Protease Activity for vWF | 5741-4 |
| Protease Inhibitor Assay for vWF | 5742-2 |
| Protein C Activity | 5785-1 |
| Protein C Antigen | 5786-9 |
| Protein S Activity | 5787-7 |
| Protein S Antigen – Free | 5788-5 |
| Protein S Antigen – Total | 5789-3 |
| Protein Z Antigen | 5759-6 |
| Prothrombin (G20210A) Mutation | 5795-0 |
| Prothrombin Fragment 1.2 (F1.2) | 5797-6 |
| Prothrombin Time | 5798-4 |
| Reptilase Time | 5799-2 |
| Residual CLL/SLL Analysis (MRD) | 5155-7 |
| Ristocetin Cofactor, vWF Activity (vWF:RCoF) | 5805-7 |
| Ristocetin Induced Platelet Aggregation (RIPA) | 5806-5 |
| Small Blue Round Cell Tumor Profile | 5177-1 |
| Smear Review (Morphology) | 5753-9 |
| Smears only | 5211-8 |
| Spindle Cell Neoplasm Profile | 5191-2 |
| T-Cell Lymphoma | 5031-0 |
| TCR V- beta Repertoire with Interpretation | 5241-5 |
| TCR V-BETA Repertoire Tech Only | 5284-5 |
| Thrombin Time (TT) | 5807-3 |
| Thrombin/Antithrombin Complex (TAT) | 5808-1 |
| Tumor of Unknown Primary | 5190-4 |
| UroVysion Assay for Bladder Cancer by FISH | 5030-2 |
| UroVysion Assay for Bladder Cancer by FISH -TC Only | 5249-8 |
| Venous Prothrombotic Risk Factor | 5989-9 |
| von Willebrand Screen- Basic | 5825-5 |
| von Willebrand Screen- Expanded | 5826-3 |
| von Willebrand’s Factor Antigen (vWF:Ag) | 5815-6 |
| von Willebrand’s Normandy Assay | 5823-0 |
| vWF Multimers | 5816-4 |
| Warfarin Pharmacogenetics | 6261-2 |
| Warfarin Pharmacogenetics | 6261-2 |
| Zap 70-Panel | 5409-8 |
| Zap 70-Panel Tech only | 5110-2 |
